Unmet medical needs of an increasing patient population to drive the Psoriatic Arthritis market

‘Global Psoriatic Therapeutics Market – Size, Share and Forecasts (2019-2026)’ from DataM Intelligence provides expert analysis into the market share, size, industry outlook, volume, major manufacturers and future trends in this industry. Probable impediments have also been discussed so as to allow the user in getting a better understanding of the key market drivers and restraints.
Psoriatic Arthritis Therapeutics Market Dynamics
The market is driven by an increase in the prevalence of psoriatic arthritis, new product development, rise in adoption of biologics for the treatment of moderate to severe psoriatic arthritis and large patient population with unmet medical needs across the globe.
Prescribed drugs for psoriatic arthritis include immune-suppressing drugs, non-steroidal drugs, and various biologics. The current research trend depicts that more emphasis is given for biologics.

Psoriatic Arthritis Therapeutics Market Segmentation
The global psoriatic arthritis therapeutics market is segmented by drug class as Nonsteroidal anti-inflammatory drugs (NSAIDs), Disease-modifying antirheumatic drugs (DMARD) and biologic drugs. By route of administration the market is segmented as oral, parenteral, and topical and by distribution channel as hospital pharmacies, retail pharmacies, and online pharmacies.
By route of administration, oral treatment is expected to dominate the psoriatic arthritis market. The Food and Drug Administration (FDA) has approved Celgene Corporation’s apremilast (Otezla), the first selective inhibitor of phosphodiesterase 4 (PDE4) prescribed for adults with moderate to severe plaque psoriasis, in March 2014.

Psoriatic Arthritis Therapeutics Market Geographical Share
Geographically, the global Psoriatic Arthritis Therapeutics market is divided into North America, Europe, South America, Asia-Pacific and the Middle East and Africa.
North America is expected to account for the highest share of the global market by 2026. According to the Centre for Disease Control and Prevention (CDC), in 2017 around 1% of the total population of North America was suffering from psoriatic arthritis. In the US, psoriatic arthritis occurs in about 2% of the population and equally among both the sexes.

Global Psoriatic Arthritis Therapeutics Market Competitive Analysis
Some of the major key players in the market are AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc., Eli Lilly and Company, UCB, Inc., Biogen Inc., and Bristol-Myers and Squibb Company. Few of the recent key developments of the major companies include –
In April 2019, China Health Authority NMPA approved Cosentyx (secukinumab) for moderate-to-severe psoriatic arthritis in adult patients who are candidates for systemic therapy or phototherapy.
In March 2019, AbbVie announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved SKYRIZI (risankizumab), an interleukin-23 (IL-23) inhibitor, for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adult patients who have an inadequate response to conventional therapies.
Checkout the space below to gather a sample research report for free-
https://www.datamintelligence.com/research-report/psoriatic-arthritis-therapeutics-market

Following content is contained in this report-
1. Global Psoriatic Arthritis Therapeutics Market Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Global Psoriatic Arthritis Therapeutics Market Definition and Overview
3. Global Psoriatic Arthritis Therapeutics Market Executive Summary
3.1. Market Snippet by Drug Class
3.2. Market Snippet by Route of Administration
3.3. Market Snippet by Distribution Channel
3.4. Market Snippet by Region
3.5. DataM CLO Scenario
4. Global Psoriatic Arthritis Therapeutics Market – Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in the prevalence of psoriatic arthritis
4.1.1.2. New product development and commercialization across the globe
4.1.1.3. Rise in adoption of biologics
4.1.2. Restraints
4.1.2.1. High cost of the drugs and treatment
4.1.2.2. Generic Erosion
4.1.2.3. Lack of standardization tools for diagnosis and treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Global Psoriatic Arthritis Therapeutics Market – Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
5.4. Epidemiology
6. Global Psoriatic Arthritis Therapeutics Market – By Drug Class
6.1. Introduction
6.2. Nonsteroidal anti-inflammatory drug (NSAID)
6.3. Disease-modifying antirheumatic drug (DMARD)
6.3.1. Antimalarials
6.3.2. Corticosteroids
6.4. Biologic drugs
6.4.1. TNF-alpha
6.4.2. IL-inhibitors
6.4.3. T cell inhibitors
7. Global Psoriatic Arthritis Therapeutics Market – By Route of Administration
7.1. Introduction
7.2. Oral
7.3. Parenteral
7.4. Topical
8. Global Psoriatic Arthritis Therapeutics Market – By Distribution Channel
8.1. Introduction
8.2. Hospital pharmacies
8.3. Retail pharmacies
8.4. Online pharmacies
9. Global Psoriatic Arthritis Therapeutics Market – By Region
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.3. Europe
9.3.1. Germany
9.3.2. U.K.
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Asia-Pacific
9.5.1. China
9.5.2. India
9.5.3. Japan
9.5.4. Australia
9.5.5. Rest of Asia Pacific
9.6. Middle East and Africa
10. Psoriatic Arthritis Therapeutics Market – Competitive Landscape
10.1. Competitive Scenario
10.2. Competitor Psoriatic Arthritis Therapeutics Strategy Analysis
10.3. Comparative Product Portfolio Analysis
10.4. Market Positioning/Share Analysis
10.5. Mergers and Acquisitions Analysis
11. Psoriatic Arthritis Therapeutics Market – Company Profiles
11.1. AbbVie, Inc. *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. Janssen Biotech, Inc.
11.3. Novartis AG
11.4. Amgen, Inc.
11.5. Celgene Corporation
11.6. Pfizer, Inc.
11.7. Eli Lilly and Company
11.8. UCB, Inc.
11.9. Biogen Inc.
11.10. Bristol-Myers and Squibb Company
12. Global Psoriatic Arthritis Therapeutics Market – Premium Insights
13. Global Psoriatic Arthritis Therapeutics Market – DataM
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us

About DataM Intelligence

DataM Intelligence 4Market Research is a Market Intelligence and Business Research firm, based in India. It aims to bridge the two main aspects of a business decision - opinion and supportive data.

DMI is currently strengthening its cross-industrial database for sectors including Chemicals, Materials, Agriculture, Healthcare Services, Animal Nutrition, Consumer Goods, Food & Beverages, Industrial Machinery and Automation among others.

Corporate Address
1st floor, Phoenix Tech Tower, Plot no: 14/46, Habsidguda, IDA-Uppal, Hyderabad-500039, Telangana

Email
info@datamintelligence.com

Phone
+1 877-441-4866

This release was published on openPR.